| Literature DB >> 31474243 |
Margit Philomène C Klok1, Philip F van Eijndhoven2, Miklos Argyelan3, Aart H Schene4, Indira Tendolkar5.
Abstract
BACKGROUND: Major depressive disorder (MDD) has been related to structural brain characteristics that are correlated with the severity of disease. However, the correlation of these structural changes is less well clarified in treatment-resistant depression (TRD). AIMS: To summarise the existing literature on structural brain characteristics in TRD to create an overview of known abnormalities of the brain in patients with MDD, to form hypotheses about the absence or existence of a common pathophysiology of MDD and TRD.Entities:
Keywords: Structural characteristics; neuro-imaging; therapy resistant depression
Year: 2019 PMID: 31474243 PMCID: PMC6737518 DOI: 10.1192/bjo.2019.58
Source DB: PubMed Journal: BJPsych Open ISSN: 2056-4724
Fig. 1Flow diagram for inclusion in the review.
Characteristics of included studies
| Author (Year) | Method | Age, years (range or s.d. | Male/female | Control group ( | Level of therapy resistance | |
|---|---|---|---|---|---|---|
| Phillips | 26 | ROI | 46 (18–65) | 8/18 | HC (28) | T&R ≥II |
| Sun | 45 | ROI | 40.8 (18–63) | 22/23 | HC (30) | T&R ≥II |
| Furtado | 45 | ROI | 37.5 (18–62) | 22/23 | HC (30) | T&R ≥II |
| Lan | 27 | WB-VBM | 41.5 (16) | 9/18 | HC (27) | T&R ≥II |
| Machino | 29 | WB-VBM | 39.6 (8.3) | 16/13 | HC (29) | T&R ≥II |
| Serra-Blasco | 22 | WB-VBM | 49 (8) | 4/18 | HC/FED/RRD (22/22/22) | T&R ≥III |
| Zhang | 15 | MTI | 33.5 (18–51) | 10/5 | HC (15) | T&R ≥II |
| Shah | 20 | WB-VBM | 48.9 (9.8) | 13/7 | HC/RfD (20/20) | T&R ≥IIIc |
| Ma | 18 | WB-VBM | 27.4 (7.74) | 11/7 | HC/DRT (17/17) | T&R ≥II |
| Young | 22 | WB-VBM | 52.1 (33.9–68) | 8/14 | HC (21) | T&R ≥IV |
| Guo | 23 | DTI | 27.4 (7.74) | 11/12 | HC (19) | T&R ≥II |
| Peng | 30 | DTI | 26.9 (5.28) | 19/11 | HC (25) | T&R ≥IIIc |
| de Diego-Adelino | 18 | DTI | 48.5 (7.3) | 3/15 | HC/FED/RRD (17/19/15) | T&R ≥II |
| Maller et | 115 | ROI | 39.6 (29–62) | 61/54 | HC (86) | T&R ≥II |
ROI, region of interest; HC, healthy control; T&R, Thase and Rush staging model: ≥II, non-responsiveness to at least two courses of antidepressant medications for at least 6 weeks; ≥III, stage II resistance plus failure of an adequate trial of tricyclic antidepressant; ≥IV, stage III resistance plus failure of an adequate trial of a monoamine oxidase inhibitors; WB-VBM, whole-brain voxel-based morphometry; FED, first-episode depression; RRD, remitted–recurrent depression; MTI, magnetisation transfer imaging; RfD, recovered from depression; DRT, depression responsive to treatment; DTI, diffusion tensor imaging.
Range or s.d. depending on the source of information.
Gender included as covariate.
Non-responsiveness to at least two courses of antidepressant medications for at least 4 weeks.